Acura Pharmaceuticals
Manufacturing · Illinois, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
616 N North Ct Ste 120, Palatine, Illino...Phone Number
(847) 705-7709Website
www.acurapharm.comRevenue
<$5 MillionStock Symbol
ACURIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Acura Pharmaceuticals
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of products to address medication abuse and misuse. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide. The company was founded in 1935 and is based in Palatine,...Explore more
Acura Pharmaceuticals Org Chart
AB
Vice President, Technical Affairs
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Acura Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Acura Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Acura Pharmaceuticals
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Acura Pharmaceuticals has new funding data
Check if Acura Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Check out if Acura Pharmaceuticals is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Acura Pharmaceuticals recently announced quarterly report
Acura Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Acura Pharmaceuticals launches new products
Recommended Actions
Find VP level buyers at Acura Pharmaceuticals
Find more new buyers
Compare Similar Companies to Acura Pharmaceuticals
Compare insights from companies similar to Acura Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Acura Pharmaceuticals
<$5M
1-10
Public
$16.6M
1935
RS
Robert SeiserVice President, Treasurer & Corporate Controller
Company Profile Activity
Activity Insights
Acura Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Acura Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Acura Pharmaceuticals.
Acura Pharmaceuticals financials insights
Gather financial insights about Acura Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2006
Debt
$534K
2007
Debt
$600K
2014
Debt
$10M
2017
Stock Offering
$5M
2020
Debt
$150K
2021
Debt
$266K
Acura Pharmaceuticals Tech Stack
A closer look at the technologies used by Acura Pharmaceuticals
See more technologies
Most Recent Scoops
Person-Based
Contracts
Funding
Funding
Funding
Acura Pharmaceuticals has received an SBA PPP loan in the amount of $266,840 from JPMorgan Chase resulting in the retention of 12 jobs.
Funding
Acura Pharmaceuticals News & Media
Debt-laden Acura Pharmaceuticals (ACUR) flags May 2026 financing and bankruptcy risk
Acura Pharmaceuticals adds AD Pharma loans, lifting secured debt to $10.3M, and warns it may scale back or terminate operations and seek bankruptcy without new financing by end of May 2026.Acura Pharmaceuticals secures additional financing By Investing.com
Acura Pharmaceuticals secures additional financingAcura Pharmaceuticals secures additional financing By Investing.com
Acura Pharmaceuticals secures additional financingAcura Pharmaceuticals Provides Development Update on LTX-03
PALATINE, Ill., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) today announced that the LTX-03 (hydrocodone bitartrate and acetaminophen) tablets using Acura’s LIMITx technology manufactured in the three New Drug Application (“NDA”) required registration batches successfully passed testing at the six month time point in an ongoing shelf life study when stored at normal temperature and humidity conditions, also known as controlled room temperature (“CRT”). The patente
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Acura Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of products to address medication abuse and misuse. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine a... Read More
